Steven Coutré

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial”.

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood(2022)10.1182/blood.2021014960

N/A

5.5DataRank · unranked

240 citations

Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos +17 more

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-2856

N/A

4.5DataRank · unranked

184 citations

Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum +9 more

Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7500

N/A

0.687DataRank · unranked

14 citations

Jun Yin, Jennifer R. Brown, Shira Dinner, Gerard Lozanski, Richard F. Little +15 more

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Blood(2021)10.1182/blood.2020010146

N/A

0.538DataRank · unranked

35 citations

Curtis A. Hanson, Renee C. Tschumper, Connie Lesnick, Esteban Braggio, Elisabeth Paietta +17 more

Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1929959

N/A

0DataRank · unranked

13 citations

Steven Coutré, Hervé Ghesquières, Ira Pastan, Robert J. Kreitman, Ilana R. Yurkiewicz

Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps7567

N/A

0DataRank · unranked

3 citations

Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael Fisch +9 more

Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas

Blood Advances(2023)10.1182/bloodadvances.2023011997

N/A

0DataRank · unranked

5 citations

Joseph G. Schroers‐Martin, Brian J. Sworder, Karan R. Kathuria, Stefan Alig, Matthew J. Frank +8 more

Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e20004

N/A

0DataRank · unranked

0 citations

Sumithra J. Mandrekar, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander +15 more